Cancer Research Success Story
It is a privilege to work with our patients who volunteer to participate in cancer research clinical trials. We feel great pride when one of the drugs studied at Holy Cross Hospital generates positive data to attain FDA approval and therefore help many more patients across the country.
Ipilimumab is an immunotherapy treatment for metastatic melanoma and was on trial here at Holy Cross. It received FDA approval for treatment of unresectable metastatic melanoma and is commercially available under the name Yervoy.
Holy Cross opened the study of Ipilimumab in 2008 under the leadership of Dr Ena Segota. Janet Copen, RN, BSN was the study coordinator. The study was sponsored by Bristol-Myers Squibb and our study site just closed.
The study was designed for patients with stage III or IV unresectable metastatic melanoma. The five year survival rate for stage IV melanoma is only about 15% to 20% (American Cancer Society http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-...) .
One of our patients continues to benefit well over three and a half years after enrollment. He recently stopped by to visit cancer center staff and expressed how happy he is. We are sharing with you how happy we are for him and other patients who can benefit from this treatment.
Regulatory Coordinator, Bienes Cancer Center and Orthopedic Institute